Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-11-26
- Last Posted Date
- 2018-08-10
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT00003202
- Locations
- 🇺🇸
Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States
Combination Chemotherapy as Induction Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-11-25
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00003037
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer
- First Posted Date
- 2003-11-24
- Last Posted Date
- 2018-11-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 184
- Registration Number
- NCT00002836
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer
- Conditions
- First Posted Date
- 2003-11-13
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT00072787
- Locations
- 🇺🇸
Lovelace Sandia Health System, Albuquerque, New Mexico, United States
🇺🇸University of New Mexico - Albuquerque, Albuquerque, New Mexico, United States
🇺🇸New Mexico VA Health Care System, Albuquerque, New Mexico, United States
Edotecarin and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
- Conditions
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00072332
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma
- Conditions
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00072124
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1
- Registration Number
- NCT00072215
- Locations
- 🇺🇸
Broward General Medical Center, Fort Lauderdale, Florida, United States
🇺🇸Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸Palm Beach Cancer Institute - West Palm Beach, West Palm Beach, Florida, United States
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 94
- Registration Number
- NCT00003141
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-11-05
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 78
- Registration Number
- NCT00072527
- Locations
- 🇺🇸
McDonough District Hospital, Macomb, Illinois, United States
🇺🇸Hudner Oncology Center at Saint Anne's Hospital, Fall River, Massachusetts, United States
🇺🇸Saint Luke's Hospital, Chesterfield, Missouri, United States
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma
- Conditions
- Interventions
- Biological: filgrastimBiological: sargramostimDrug: carboplatinDrug: cisplatinDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: etoposideDrug: etoposide phosphateDrug: ifosfamideDrug: isotretinoinDrug: melphalanDrug: thiotepaDrug: vincristine sulfateProcedure: conventional surgeryProcedure: peripheral blood stem cell transplantationRadiation: radiation therapy
- First Posted Date
- 2003-10-09
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 42
- Registration Number
- NCT00017368
- Locations
- 🇺🇸
CCOP - Columbia River Oncology Program, Portland, Oregon, United States
🇺🇸Floating Hospital for Children, Boston, Massachusetts, United States
🇺🇸CCOP - Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.